FDA Approves Resmetirom, First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
U.S. Food and Drug Administration (FDA) approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH).